Newbury Pharmaceuticals Secured Ten-Year Supply Deal
The firm will distribute 40 injectable medicines in Iraq under its own brand through a new manufacturing partnership.
Updated on Sept. 30, 2026 in Healthcare
Live Poll
Do you believe partnerships with foreign pharmaceutical firms improve medicine access in your area?
Newbury Pharmaceuticals AB has signed a ten-year exclusivity agreement with a Chinese manufacturer to supply a portfolio of 40 injectable medicines. The company has begun applying for an import licence to bring these acute care products into the Iraqi market.
Why it matters
This expansion provides the firm with a branded entry into Iraq's hospital and acute care sectors. The move highlights the strategic use of manufacturing partnerships to navigate international regulatory hurdles for specialized medical supply chains.
The deal covers 40 injectable medicines over a 10-year exclusivity period. The total number of hospitals and acute care facilities affected by the planned import license application remains unknown.
The players
Newbury Pharmaceuticals AB
A Swedish pharmaceutical company that operates through international subsidiaries to supply specialty medicines.
The details
The partnership is managed through the Swedish company's subsidiary, Newbury Pharmaceuticals S.A. By applying for an import licence, the firm aims to facilitate the supply of injectable medicines to Iraq before securing full marketing authorisation. These products will be sold exclusively under the Newbury Pharmaceuticals brand name.
Timeline
September 30, 2026: The exclusivity agreement was signed.
10 years: The total duration of the contract with the manufacturing partner.
Market Landscape
The move follows a standard industry pattern of leveraging third-party manufacturing to scale branded distribution into emerging markets. It reflects the broader trend of pharmaceutical firms navigating the WHO Model List of Essential Medicines regulatory standards to reach hospital segments.
Operators in the pharmaceutical supply chain should monitor whether the Iraqi import licence is granted, as it could accelerate market entry for similar hospital-focused portfolios. Finance teams should observe how this branded licensing strategy impacts margin performance compared to generic-only distribution models.
The takeaway
The deal demonstrates how small-to-midsize firms can utilize manufacturing partnerships to enter new geographies without owning production facilities. Management should track the success of this import licence application as a signal for the speed of regulatory approval in the region.
Further reading
For more on how companies navigate international drug regulations, visit the Healthcare section.
Source note: This article includes information reported by Iraq Business News | All the latest business news from Iraq.
Live Poll
Do you believe partnerships with foreign pharmaceutical firms improve medicine access in your area?
